Tau Imaging of Chronic Traumatic Encephalopathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02191267 |
|
Recruitment Status :
Completed
First Posted : July 16, 2014
Results First Posted : May 17, 2018
Last Update Posted : May 17, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Chronic traumatic encephalopathy (CTE) is a progressive degenerative brain disease with symptoms that include memory loss, problems with impulse control, and depression that can lead to suicide. As the disease progresses, it can lead to dementia. Currently CTE can only be diagnosed postmortem where an over-accumulation of a protein called tau is observed. There is now a new experimental measure that makes it possible, for the first time, to measure tau protein in the living human brain using a novel positron emission tomography (PET) ligand, [F-18] AV-1451 (aka, [18F]-T807).
The main objective of this study is to use a novel PET approach to measure tau accumulation in the brain. The presence of CTE at autopsy in deceased National Football League (NFL) players has been well documented. Accordingly, we will conduct this study in a group of retired NFL players who have clinical symptoms of CTE and are suspected of having CTE based on high levels of tau in their spinal fluid and abnormalities seen on research brain scans. We will compare them with a control group of former elite level athletes who have not experienced any brain trauma, deny any clinical symptoms, and who have completely normal spinal fluid tau and amyloid levels, and brain scans. We will also include a group of subjects with AD. All participants will be recruited from ongoing studies, headed by the Partnering PI of this proposal, Dr. Robert Stern, at the Boston University Center for the Study of Traumatic Encephalopathy and the Alzheimer's Disease Center. We will use both a beta amyloid PET scan ([18F]-florbetapir) and a tau PET scan ([18F]-T807) on consecutive days. With the beta amyloid scan we expect little or no evidence of amyloid in the NFL players with presumed CTE, and no evidence of amyloid in the control group of athletes with no history of repetitive brain trauma. In contrast we expect to see beta amyloid accumulation in the AD patient brains. With the new tau ligand, we expect that the NFL players with presumed CTE will show elevated levels of tau protein in the brain, which will not be observed in athletes without a history of brain trauma, but which will be seen in the AD patients' brains.
Another goal is to use the latest MRI technologies to develop specific tau imaging biomarkers that correlate with the PET and spinal fluid tau measures but without the radiation of PET or invasiveness of spinal taps. The development of these surrogate imaging markers of tau, is critically important to diagnosing CTE. This in turn will lead to studies relevant to treatment and prevention of this devastating disease. Finally, as an exploratory method of examining possible genetic risk for CTE, we will also use cutting edge genetic analysis of blood samples from subjects in this proposal and compare tau load, measured by PET tau ligand uptake and cerebrospinal fluid (CSF) p-tau level, with a measure of genetic susceptibility to tau load, referred to as the genetic risk score for tau.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Traumatic Encephalopathy | Radiation: [F18]-T807 Radiation: [F18]-Florbetapir Device: MRI/MRS Genetic: Genetic Analysis for Genetic Risk Score for Tau. | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Tau Imaging of Chronic Traumatic Encephalopathy |
| Study Start Date : | January 2015 |
| Actual Primary Completion Date : | September 30, 2016 |
| Actual Study Completion Date : | September 30, 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Presumed CTE Group
Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
|
Radiation: [F18]-T807
[F18]-T807 PET Scan to measure tau deposition in the brain.
Other Name: [F-18] AV-1451 Radiation: [F18]-Florbetapir [F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
Other Name: Amyvid Device: MRI/MRS Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
Other Names:
Genetic: Genetic Analysis for Genetic Risk Score for Tau. DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles. |
|
Experimental: Control Group
Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
|
Radiation: [F18]-T807
[F18]-T807 PET Scan to measure tau deposition in the brain.
Other Name: [F-18] AV-1451 Radiation: [F18]-Florbetapir [F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
Other Name: Amyvid Device: MRI/MRS Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
Other Names:
|
|
Experimental: AD Dementia Group
Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
|
Radiation: [F18]-T807
[F18]-T807 PET Scan to measure tau deposition in the brain.
Other Name: [F-18] AV-1451 Radiation: [F18]-Florbetapir [F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
Other Name: Amyvid Device: MRI/MRS Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
Other Names:
|
- Tau Protein Uptake.. [ Time Frame: Day 1 - of 2 day study. ]Whole brain mean (and standard deviation) cortical value derived from standardized uptake value ratio (SUVr). Each [F18]-T807 tau scan consisted of a 60-minute dynamic acquisition after bolus intravenous injection of 10 mCi of [18F]-T807, followed by a second 20-minute dynamic imaging (list mode) acquisition from 80-100 minutes. SUVr images were constructed from the sum of the 80-100 minute frames resulting in late SUVr distribution maps.
- Beta-Amyloid (Aβ) Protein Uptake. [ Time Frame: Day 2 - of 2 day study. ]Mean and standard deviation for standardized uptake value ratios (SUVr) for posterior cingulate, superior parietal, lateral frontal, medial frontal, lateral temporal, and occipital brain regions. Each [F18]-Florbetapir (Beta-Amyloid) scan consisted of a 70-minute dynamic acquisition after bolus intravenous injection of 10 mCi of [18F]-Florbetapir. SUVr images were constructed from the sum of the 50-70 minute frames resulting in late SUVr distribution maps.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 69 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
-
Presumed CTE Group (includes 20 former NFL players who will have already participated in the NIH-funded R01 "DETECT" (Diagnosis and Evaluation of Traumatic Encephalopathy with Clinical Tests) study (Stern, PI; Shenton, Neuroimaging Site PI). Eligibility criteria for presumed CTE group and the control group are based on findings from the DETECT study.
Inclusion Criteria:
- significant cognitive impairment (and impairment in at least one of the following):
- behavioral (e.g., impulsivity, aggression),
- mood (e.g., elevated depression measures, elevated suicidality),
- and/or motor (e.g., impairments evidenced in neurological examination;
- demonstrated abnormalities on svMRI, DTI, or MRS
Exclusion Criteria:
- weight > 350 lbs
- known metallic implants preventing MRI
- history of stroke
- non-English speaking
- significant vision or hearing impairment
- unable to provide written informed consent
-
Control Group (comprised of 5 male participants selected from 50 control subjects in the DETECT study).
Inclusion Criteria:
- no history of mTBI or exposure to repetitive brain trauma
- normal functioning on DETECT clinical measures
- no abnormalities on svMRI, DTI, or MRS
Exclusion Criteria:
- weight > 350 lbs
- known metallic implants preventing MRI
- history of stroke or other neurological disease
- non-English speaking
- significant vision or hearing impairment
- AD Dementia Group (comprised of 5 male participants recruited from the BU Alzheimer's Disease Center (ADC) Clinical Core Registry (Dr. Stern, PI).
Inclusion Criteria:
- diagnosis of Dementia due to AD using the NIA-AA (National Institute on Aging-Alzheimer's Association) criteria
- Clinical Dementia Rating Global Score of 1.0,
- a positive florbetapir PET study,
- CSF p-tau/Aβ consistent with AD.
Exclusion Criteria:
- history of TBI, mTBI or or exposure to repetitive brain trauma
- weight > 350 lbs
- known metallic implants preventing MRI
- history of stroke or other neurological disease
- non-English speaking
- significant vision or hearing impairment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02191267
| United States, Massachusetts | |
| Boston University Medical Center | |
| Boston, Massachusetts, United States, 02118 | |
| Brigham and Women's Hospital | |
| Boston, Massachusetts, United States, 02215 | |
| Principal Investigator: | Martha E. Shenton, Ph.D. | Brigham and Women's Hospital |
| Responsible Party: | Martha E Shenton, Director, Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT02191267 |
| Other Study ID Numbers: |
2014P000035 |
| First Posted: | July 16, 2014 Key Record Dates |
| Results First Posted: | May 17, 2018 |
| Last Update Posted: | May 17, 2018 |
| Last Verified: | April 2018 |
|
CTE Positron Emission Topography Tau Beta-amyloid |
Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Diffusion Tensor Imaging |
|
Brain Diseases Brain Injuries, Traumatic Chronic Traumatic Encephalopathy Central Nervous System Diseases Nervous System Diseases Brain Injuries |
Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Brain Injury, Chronic Neurodegenerative Diseases |